Taste-masked pharmaceutical compositions

• US 9,884,014 B2
• Filed: 10/12/2005
• Issued: 02/06/2018
• Est. Priority Date: 10/12/2004
• Status: Active Grant

• Current Assignee: Adare Pharmaceuticals, Inc.
• Original Assignee: Adare Pharmaceuticals, Inc.
• Inventors: Venkatesh, Gopi M.
• Primary Examiner(s): BREDEFELD, RACHAEL EVA
• Application Number:
  US11/248,596
• Publication Number:
  US 20060078614A1
• Time in Patent Office: 4,500 Days
• Field of Search: 424470
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short T_max). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.

Claims

1. A pharmaceutical composition comprising:

(1) a plurality of taste-masked particles, wherein each taste-masked particle comprises;

(a) a drug-containing core particle;

(b) a taste-masking membrane disposed on said drug-containing core particle comprising a combination of a water-insoluble polymer and a gastrosoluble polymer, wherein the water-insoluble polymer is selected from the group consisting of ethylcellulose, polyvinyl acetate, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, methacrylate copolymers and combinations thereof, and the gastrosoluble polymer is selected from the group consisting of maltodextrin, aminoalkyl methacrylate copolymer, polyvinylacetate diethylaminoacetate, and combinations thereof;

wherein the ratio of the water-insoluble polymer to the gastrosoluble polymer in the taste-masking membrane ranges from about 95/5 to about 65/35 and the pharmaceutical composition releases greater than or equal to about 60% of the total amount of drug in 30 minutes when tested for dissolution using United States Pharmacopoeia Apparatus 2 using paddles at 50 rpm in 900 mL of pH 1.2 buffer; and

wherein said taste-masked particles release not more than about 10% of the total amount of drug in about 3 minutes when dissolution tested in simulated saliva fluid at pH about 6.8; and

(2) a plurality of rapidly-dispersing microgranules having an average particle size of not more than about 400 μ

m comprising (i) a disintegrant and (ii) a sugar alcohol or a saccharide or a combination thereof, wherein each of said disintegrant and sugar alcohol or saccharide is present in the form of particles having an average particle diameter of not more than about 30 μ

m, and wherein the pharmaceutical composition is an orally disintegrating tablet.

2. The pharmaceutical composition of claim 1 comprising one or more drug(s) present in sufficient quantities to be administered orally to a patient in need thereof at a prescribed dosing regimen to provide therapeutic efficacy.

3. The pharmaceutical composition of claim 1 wherein the drug-containing particle comprises a drug-layered bead comprising an inert particle coated with one or more pharmaceutically acceptable drug(s).

4. The pharmaceutical composition of claim 1, wherein the drug-containing particle comprises a microgranule or an extruded and spheronized pellet, wherein the microgranule or pellet comprises (1) one or more pharmaceutically acceptable drug(s), (2) a polymeric binder, and (3) a filler and/or diluent.

5. The pharmaceutical composition of claim 1, wherein said drug requires taste-masking.

6. The pharmaceutical composition of claim 1, wherein the drug is selected from the group consisting of diphenhydramine, ranitidine, cimetidine, famotidine, astemizole, cetirizine, fexofenadine, omeprazole, lansoprazole, sumatriptan, rezitriptan, eletriptan, zolmitriptan, ondansetron, granisetron, clonazepam, tiagabine, tizanidine, zolpidem, zaleplon, zafirlukast, montelukast, sildenafil, tadalafil, pharmaceutically acceptable salts thereof, and combinations thereof.

7. The pharmaceutical composition of claim 1 wherein the membrane thickness ranges from about 5% to 50% by weight of the coated particle.

8. The pharmaceutical composition of claim 1 wherein the water-insoluble polymer comprises ethylcellulose and the gastrosoluble polymer comprises an aminoalkyl methacrylate copolymer.

9. The pharmaceutical composition of claim 1 wherein the sugar alcohol or saccharide to disintegrant ratio is from about 90/10 to about 99/1.

10. The pharmaceutical composition of claim 1, wherein the ratio of rapidly-dispersing microgranules to taste-masked particles ranges from about 6/1 to about 2/1.

11. The pharmaceutical composition of claim 1 wherein the rapidly-dispersing microgranules comprise a disintegrant selected from the group consisting of crosslinked polyvinylpyrrolidone, sodium starch glycolate, crosslinked sodium carboxymethylcellulose, low-substituted hydroxypropylcellulose and mixtures thereof.

12. The pharmaceutical composition of claim 1, wherein the average particle size of the drug-containing core particle is not more than about 400 μ

M.

13. The pharmaceutical composition of claim 1, wherein said orally disintegrating tablet has a friability of not more than about 1%.

14. The pharmaceutical composition of claim 1, wherein said orally disintegrating tablet disintegrates on contact with the saliva in the oral cavity within approximately 60 seconds.

15. The pharmaceutical composition of claim 1, wherein the rapidly dispersing microgranules comprise a sugar alcohol or a saccharide selected from the group consisting of mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, and combinations thereof.

16. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition exhibits acceptable taste-masking when placed in the oral cavity for 60 seconds.

17. The pharmaceutical composition of claim 1, wherein the rapidly dispersing microgranules have an average particle size of not more than 300 μ

m.

18. The pharmaceutical composition of claim 1, wherein the ratio of the water-insoluble polymer to the gastrosoluble polymer in the taste-masking membrane ranges from about 85/15 to about 65/35.

19. A method of manufacturing a pharmaceutical composition comprising:

(a) preparing core particles comprising a drug; and

(b) coating the core particles by applying a membrane comprising a mixture of water-insoluble polymer and a gastrosoluble polymer wherein the water-insoluble polymer is selected from the group consisting of ethylcellulose, polyvinyl acetate, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, methacrylate copolymers and combinations thereof and the gastrosoluble polymer is selected from the group consisting of maltodextrin, aminoalkyl methacrylate copolymer, polyvinylacetate diethylaminoacetate, and combinations thereof;

wherein the ratio of the water-insoluble polymer to the gastrosoluble polymer in the taste-masking membrane ranges from about 95/5 to about 65/35;

(c) granulating particles of a sugar alcohol and/or a saccharide, each particle of sugar alcohol and/or saccharide having an average particle diameter of not more than 30 μ

m, with a disintegrant having an average particle diameter of not more than 30 μ

m to produce rapidly-dispersing microgranules with an average particle size of not more than about 400 μ

m;

(d) blending the membrane coated microparticles of step (b) with the rapidly-dispersing microgranules of step (c) at a ratio of about ⅙

to about ½

; and

(e) compressing the blend of step (d) into orally disintegrating tablets.

20. The method of claim 19 wherein the water-insoluble polymer comprises ethylcellulose and the gastrosoluble polymer comprises an aminoalkyl methacrylate copolymer.

21. The method of claim 19, wherein said step of compressing (e) comprises utilizing a conventional rotary tablet press equipped with an external lubrication system to pre-lubricate the dies and punches.

22. The method of claim 19, wherein the orally disintegrating tablet, when tested for dissolution using United States Pharmacopoeia Apparatus 2 using paddles at 50 rpm in 900 mL buffer, release not more than about 10% of the total amount of the drug in about 3 minutes in a simulated saliva buffer at pH 6.8 and greater than or equal to about 60% of the total amount of the drug in about 30 minutes in an acidic buffer at pH 1.2.

23. The method of claim 19 wherein said rapidly-dispersing microgranules have an average particle size of not more than 300 μ

m.

24. The method of claim 19, wherein the membrane is present in an amount of from about 5% to about 50% based on the total weight of the coated particles.

25. The method of claim 19, wherein the pharmaceutical composition exhibits acceptable taste-masking when the composition is placed in the oral cavity for 60 seconds.

26. The method of claim 19, wherein the pharmaceutical composition releases not less than about 60% of the total amount of the drug in 30 minutes when tested for dissolution using United States Pharmacopeia Apparatus 2 using paddles at 50 rpm in 900 mL of pH 1.2 buffer.

27. The method of claim 19, wherein the ratio of the water-insoluble polymer to the gastrosoluble polymer in the taste-masking membrane ranges from about 85/15 to about 65/35.